LQLei Qian

Lei Qian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lei Qian has a total of 161 co-authors. Here are the top co-authors by number of shared publications:

  • Huan Deng

    Innovent Biologics, Inc., Suzhou, China

    9 shared publications
  • Hongwei Jiang

    The First Affiliated Hospital, and College of Clinical Medicine, State Key Laboratory of Light Superalloys, Henan University of Science and Technology, Luoyang, China; State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China

    7 shared publications
  • Li Li

    Innovent Biologics, Inc., Suzhou, China

    6 shared publications
  • Qingyang Ma

    Innovent Biologics, Inc., Suzhou, China

    6 shared publications
  • Han Han-Zhang

    Innovent Biologics, Inc., Suzhou, China

    4 shared publications
  • Haoyu Li

    Innovent Biologics, Inc., Suzhou, China

    4 shared publications

Latest Publications

  • Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial

    by Linong Ji, Hongwei Jiang, Zhifeng Cheng, Xiaoli Li, Shuguang Pang, Yawei Zhang, Wei Qiu, Qingyang Ma, Zihan Liu, Yanqi Wang, et al.


  • Mazdutide versus placebo in Chinese adults with type 2 diabetes

    by Dalong Zhu, Jiajun Zhao, Hanqing Cai, Xuan Chu, Shuangling Xiu, Chengwei Song, Zhifeng Cheng, Hongyi Cao, Hongwei Jiang, Lili Zhang, et al.

    Despite advances in type 2 diabetes (T2D) management, unmet needs remain for therapies that effectively control hyperglycaemia while addressing the comorbid metabolic disorders1, 2. Here we assessed the efficacy and safety of the dual glucagon receptor (GCGR)/glucagon-like peptide-1 receptor (GLP-1R) agonist mazdutide monotherapy versus placebo in Chinese adults with T2D inadequately controlled with diet and exercise alone. In this phase 3 trial, 320 participants (mean HbA1c of 8.24%, BMI of 28.2 kg/m2, and diabetes duration of 1.9 years) were randomised 1:1:1 to receive weekly subcutaneous injections of mazdutide 4 mg, 6 mg, or placebo for 24 weeks, followed by a 24-week extended mazdutide treatment. At week 24, mazdutide significantly reduced HbA1c versus placebo (primary endpoint): -1.57% with mazdutide 4 mg and -2.15% with mazdutide 6 mg, versus -0.14% with placebo, with treatment differences of -1.43% and -2.02% (both p p1c target (1c p <0.0001). The most common adverse events—diarrhoea, decreased appetite, and nausea—were consistent with GLP-1R agonists. These results establish mazdutide monotherapy as an effective intervention providing clinically meaningful glycaemic control and weight reduction alongside a favourable safety profile in this population.


  • Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes

    by Lixin Guo, Bo Zhang, Xia Xue, Xin Zhang, Hanqing Cai, Hongwei Jiang, Lili Zhang, Ping Jin, Xiaojing Wang, Zhifeng Cheng, et al.

    Mazdutide is a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist developed for the treatment of type 2 diabetes (T2D) 1. This study assessed the efficacy and safety of mazdutide versus dulaglutide in participants with T2D on background oral anti-diabetic drugs. In this randomised phase 3 study, 731 participants with T2D were randomised 1:1:1 to receive mazdutide 4 mg, mazdutide 6 mg or dulaglutide 1.5 mg for 28 weeks. Both mazdutide doses demonstrated non-inferiority and superiority to dulaglutide 1.5 mg in mean change in HbA1c from baseline to week 28, with the least squares (LS) mean treatment difference of −0.24% (p=0.0032) for mazdutide 4 mg and −0.30% (p=0.0003) for mazdutide 6 mg vs dulaglutide 1.5 mg. Significantly greater weight reductions were achieved with mazdutide versus dulaglutide, with LS mean treatment difference of −3.78% for mazdutide 4 mg and −5.76% for mazdutide 6 mg vs dulaglutide (both p1c p1c and body weight compared with dulaglutide 1.5 mg in Chinese participants with T2D. Mazdutide was generally safe, with a higher incidence of gastrointestinal adverse events than dulaglutide.


  • Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

    by Yingying Luo, Hongwei Jiang, Bimin Shi, Hanqing Cai, Haifang Wang, Shu Li, Wei Qiu, Yunfeng Li, Runze Zhou, Huan Deng, et al.


  • Efficacy and Safety of Efdamrofusp Alfa versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration

    by Junran Sun, Yanping Song, Yuanyuan Gong, Liming Tao, Hong Wang, Xiangwen Shu, Ying Wen, Ling Cui, Jian Ye, Shujie Lu, et al.


  • Open Access

    A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

    by Linong Ji, Hongwei Jiang, Zhifeng Cheng, Wei Qiu, Lin Liao, Yawei Zhang, Xiaoli Li, Shuguang Pang, Lihui Zhang, Liming Chen, et al.

    Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy and safety of 24-week treatment of mazdutide up to 6 mg in Chinese overweight adults or adults with obesity, as an interim analysis of a randomised, two-part (low doses up to 6 mg and high dose of 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913). Overweight adults (body-mass index [BMI] ≥24 kg/m2) accompanied by hyperphagia and/or at least one obesity-related comorbidity or adults with obesity (BMI ≥ 28 kg/m2) were randomly assigned (3:1:3:1:3:1) to once-weekly mazdutide 3 mg, 4.5 mg, 6 mg or matching placebo at 20 hospitals in China. The primary endpoint was the percentage change from baseline to week 24 in body weight. A total of 248 participants were randomised to mazdutide 3 mg (n = 62), 4.5 mg (n = 63), 6 mg (n = 61) or placebo (n = 62). The mean percentage changes from baseline to week 24 in body weight were −6.7% (SE 0.7) with mazdutide 3 mg, −10.4% (0.7) with 4.5 mg, −11.3% (0.7) with 6 mg and 1.0% (0.7) with placebo, with treatment difference versus placebo ranging from −7.7% to −12.3% (all p < 0.0001). All mazdutide doses were well tolerated and the most common adverse events included diarrhoea, nausea and upper respiratory tract infection. In summary, in Chinese overweight adults or adults with obesity, 24-week treatment with mazdutide up to 6 mg was safe and led to robust and clinically meaningful body weight reduction.


  • Open Access

    Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial

    by Yong Huo, Beijian Chen, Qiufang Lian, Shuqing Wang, Lu Liu, Di Lu, Yanling Qu, Guanzhong Zheng, Lipeng Li, Yuan Ji, et al.


  • Open Access

    Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

    by Meng Chai, Yongming He, Wang Zhao, Xuebin Han, Guoyan Zhao, Xueping Ma, Ping Qiao, Dongmei Shi, Yuyang Liu, Wei Han, et al.

    Background: Heterozygous familial hypercholesterolemia (HeFH) is largely underdiagnosed and undertreated in China where few patients achieved recommended target levels of low density lipoprotein cholesterol (LDL-C). We conducted the first randomized, placebo-controlled clinical trial in Chinese patients with HeFH to assess the efficacy and safety of tafolecimab, a novel fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody. Methods: Patients diagnosed with HeFH by Simon Broome criteria and on a stable lipid-lowering therapy for at least 4 weeks were randomized 2:2:1:1 to receive subcutaneous tafolecimab 150 mg every 2 weeks (Q2W), tafolecimab 450 mg every 4 weeks (Q4W), placebo Q2W or placebo Q4W in the 12-week double-blind treatment period. After that, participants received open-label tafolecimab 150 mg Q2W or 450 mg Q4W for 12 weeks. The primary endpoint was the percent change from baseline to week 12 in LDL-C levels. Secondary endpoints included proportion of participants achieving ≥50% LDL-C reductions and proportion of participants with LDL-C P P <0.0001). Meanwhile, non-HDL-C, apolipoprotein B and lipoprotein(a) levels were significantly reduced in the tafolecimab groups at week 12. The lipid-lowering effects of tafolecimab were maintained till week 24. During the double-blind treatment period, the most commonly-reported adverse events in the tafolecimab groups included upper respiratory tract infection, increased blood creatine phosphokinase, increased alanine aminotransferase, increased aspartate aminotransferase and hypertension. Conclusions: Tafolecimab administered either 150 mg Q2W or 450 mg Q4W yielded significant and persistent reductions in LDL-C levels and showed a favorable safety profile in Chinese patients with HeFH. Trial registration: ClinicalTrials.gov, NCT04179669.


  • Open Access

    A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

    by Hongwei Jiang, Shuguang Pang, Yawei Zhang, Ting Yu, Meng Liu, Huan Deng, Li Li, Liqi Feng, Baili Song, Han Han-Zhang, et al.

    The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes (T2D) and obesity has sparked considerable efforts to develop next-generation co-agonists that are more effective. We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904) to evaluate the safety and efficacy of IBI362 (LY3305677), a GLP-1 and glucagon receptor dual agonist, in Chinese patients with T2D. A total of 43 patients with T2D were enrolled in three cohorts in nine study centres in China and randomised in each cohort to receive once-weekly IBI362 (3.0 mg, 4.5 mg or 6.0 mg), placebo or open-label dulaglutide (1.5 mg) subcutaneously for 12 weeks. Forty-two patients received the study treatment and were included in the analysis, with eight receiving IBI362, four receiving placebo and two receiving dulaglutide in each cohort. The patients, investigators and study site personnel involved in treating and assessing patients in each cohort were masked to IBI362 and placebo allocation. Primary outcomes were safety and tolerability of IBI362. Secondary outcomes included the change in glycated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and post-mixed-meal tolerance test (post-MTT) glucose levels. IBI362 was well tolerated. Most commonly-reported treatment-emergent adverse events were diarrhoea (29.2% for IBI362, 33.3% for dulaglutide, 0% for placebo), decreased appetite (25.0% for IBI362, 16.7% for dulaglutide, 0% for placebo) and nausea (16.7% for IBI362, 16.7% for dulaglutide and 8.3% for placebo). HbA1c, FPG and post-MTT glucose levels were reduced from baseline to week 12 in patients receiving IBI362 in all three cohorts. IBI362 showed a favourable safety profile and clinically meaningful reductions in blood glucose in Chinese patients with T2D.